4.9 • 876 Ratings
🗓️ 24 January 2025
⏱️ 26 minutes
🧾️ Download transcript
Familial hypercholesterolemia, cardiac arrest therapy, Factor XI inhibition, and tricuspid valve interventions are the topics John Mandroa, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Familial hypercholesterolemia
II. Cardiac Arrest
III. Factor XI
IV. Tricuspid Valve Interventions
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Click on a timestamp to play from that location
0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
0:05.7 | This podcast is intended for health care professionals only. |
0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
0:15.8 | Hi, everyone. |
0:17.1 | This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week |
0:22.1 | in cardiology for January 24th, 2025. This week, familial hypercholesterolemia, cardiac arrest therapy, |
0:31.2 | factor 11 inhibition, and more on tricuspid valve interventions. I first want to say thank you to the University of Michigan |
0:39.0 | Fellows for inviting me to give cardiovascular rounds there yesterday. It is an honor to be asked |
0:44.4 | to speak anywhere, but is an especially big honor to get a fellow's invite. I spoke on atrial fibrillation |
0:51.4 | therapy focusing on areas of uncertainty. It was also great to see |
0:57.0 | my friend, Vanke Murthy, who's a true academic. All right, first topic today is familial |
1:03.5 | hypercholomia. When I started cardiology many years ago, getting the diagnosis of FH was terrible. |
1:10.4 | Early coronary disease and cardiovascular death |
1:12.5 | was highly likely. But things have changed for the better. So suggests yet another neat observational |
1:20.9 | comparison study using that national treasure the Danish Health Registry. The first author is Jacob Re, and co-authors from the Genthoff Hospital in Copenhagen, |
1:31.9 | which I've visited. |
1:33.7 | They use the registry to compare about 11,000 patients with and 9 million without FH |
1:39.7 | over a 45-year period dating back to 1978. |
1:48.1 | During follow-up, 27% of those with and without femal hypercalycelestralia died. And the key findings for individuals with FH compared to those without, |
1:56.6 | the mean age at death was 22 years younger in 1978, but in 2021, the corresponding difference |
2:05.7 | in mean age of death was only one year, 78 versus 79 years. |
2:10.9 | And when you look at a graph with age of death on the y-axis, and years on the x-axis, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.